Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Four-year data support Endologix' Powerlink AAA (abdominal aortic aneurysm) stent graft system:

This article was originally published in Clinica

Executive Summary

Endologix says that four-year data are now available to support the durability of its Powerlink stent graft system for treating abdominal aortic aneurysms (AAAs). Follow-up results from the pivotal trial found that only 24 of the 192 patients treated with the minimally-invasive device required secondary procedures, the majority of which were for type II endoleak, indicating that the need for a secondary procedure was not device-specific, the Irvine, California firm said. In addition, 97.9% of the 53 patients followed for 48 months were free from AAA-related mortality and there were no reports of graft material failure. Powerlink was approved for sale in the US in October 2004.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT057998

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel